Semaglutide for Weight Loss: Evidence & Response Factors

Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide is a GLP-1 receptor agonist medication originally developed for type 2 diabetes that has demonstrated significant weight loss effects in clinical populations. Landmark trials show average weight reductions of 10-22% depending on final dose and baseline patient characteristics, making it one of the most studied peptide medications for weight management.

While clinical evidence supports semaglutide's efficacy, individual outcomes vary considerably based on metabolic status, genetic factors, and lifestyle adherence. Understanding your personal risk profile and response potential before starting treatment can help guide more productive conversations with your healthcare provider about whether this medication aligns with your goals and health history.

Clinical Evidence: What Studies Show About Semaglutide Efficacy

The STEP trial program (Semaglutide Treatment Effect in People with obesity) demonstrated weight loss ranging from 10% at 1.7 mg weekly to 22.3% at 2.4 mg weekly over 68 weeks in non-diabetic patients. These results represent some of the largest sustained weight reductions achieved with a single medication in obesity research.

Weight loss typically plateaus by week 20-24 of treatment, with most participants stabilizing their loss by month 6. Response patterns vary: some patients achieve significant loss quickly, while others show more gradual decline. Baseline metabolic health, age, and insulin resistance level all influence the trajectory and magnitude of response.

Factors Influencing Individual Semaglutide Response

Multiple physiological and genetic factors contribute to how effectively semaglutide works in any given individual. Biomarkers including baseline insulin sensitivity, fasting glucose, inflammatory markers, and leptin levels can help predict which patients may experience more substantial weight loss. Genetic variants in GLP-1 receptor pathways and related metabolic genes also shape responsiveness and side effect tolerance.

Response Factor	Clinical Relevance
Baseline Insulin Resistance	Higher insulin resistance may predict stronger appetite suppression and metabolic benefit
GLP1R Gene Variants (rs6923761)	Genetic variants can predispose to differential GLP-1 receptor sensitivity and response magnitude
FTO Gene Variant (rs9939609)	Associated with appetite regulation; may influence baseline weight and response trajectory
MC4R Gene Variant (rs17782313)	Linked to obesity risk and appetite control; may correlate with medication responsiveness
Baseline Metabolic Health	Patients with metabolic dysfunction often show greater weight loss benefits than those with normal metabolism
Age and Sex Hormones	Estrogen status and age affect metabolic rate and may modify semaglutide's appetite-suppressing effects

Common Side Effects and Tolerance Patterns

Gastrointestinal side effects are the most frequently reported, including nausea, vomiting, constipation, and diarrhea. Most occur during dose escalation and tend to diminish over 4-8 weeks as the body adapts. Approximately 20-30% of patients discontinue due to side effect burden, though this varies by individual tolerance and dose titration approach.

Rare but serious adverse events include pancreatitis, gallbladder disease, and thyroid concerns. Patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 should not use semaglutide. Working with a healthcare provider to monitor for warning symptoms during treatment is essential for safe use.

Who Benefits Most: Medical Suitability and Personalization

Semaglutide is most appropriate for adults with a BMI of 30 or higher, or 27 or higher with weight-related comorbidities such as type 2 diabetes, hypertension, or sleep apnea. Medical history, current medications, and prior drug responses all inform whether semaglutide or alternative approaches may be more suitable for individual patients.

A qualified healthcare provider should conduct comprehensive evaluation including metabolic labs, cardiovascular screening, and medication interaction review before initiating treatment. Genetic and biomarker assessment can provide additional context about your individual predispositions to GLP-1 response, helping your provider tailor dose escalation and monitoring strategies to your specific risk profile.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your individual predispositions in GLP-1 receptor pathways and related metabolic genes. The test examines key variants including GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313—all associated with appetite regulation and metabolic response. This information should be interpreted with a qualified healthcare provider as part of a comprehensive medical assessment.

Genetic predisposition does not predict your exact semaglutide response, but rather indicates which pathways may be more or less sensitive to GLP-1 signaling in your body. Combined with biomarker assessment (insulin sensitivity, inflammatory status, metabolic markers), genetic insights can help your provider understand whether semaglutide aligns with your metabolic profile and what dose or monitoring approach may be most appropriate for you.

PlexusDx compounded semaglutide options (injection $149/mo or oral from $249/mo) can be discussed with your provider once you understand your individual factors. Our Precision Peptide Genetic Test ($99 add-on or $298 standalone) supports more informed provider conversations about whether GLP-1 therapy matches your genetics and metabolic needs, helping guide personalized treatment planning.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How much weight can I expect to lose with semaglutide?

Clinical trials show average weight loss of 10-22% depending on dose and individual factors. Individual results vary significantly based on baseline metabolism, adherence, and genetic predispositions. Your healthcare provider can estimate realistic expectations based on your specific profile.

Does semaglutide work for everyone?

No. Approximately 10-15% of trial participants experience minimal weight loss despite adequate dosing. Genetic variants, baseline insulin sensitivity, and metabolic status influence responsiveness. Some individuals benefit more from alternative medications or approaches.

What is the difference between compounded semaglutide and branded versions?

PlexusDx offers compounded semaglutide prepared by licensed 503A pharmacies, which differs from branded products. Compounded versions are not FDA-approved but formulated under pharmacy regulations. Discuss with your provider whether compounded or branded options suit your medical needs and preferences.

What are the most serious risks of semaglutide?

Serious but rare risks include pancreatitis, gallbladder disease, and thyroid complications. Patients with medullary thyroid cancer history or MEN2 syndrome should not use semaglutide. Regular monitoring by a healthcare provider helps detect and manage any concerning symptoms early.

Can genetic testing predict how well semaglutide will work for me?

The Precision Peptide Genetic Test reveals predispositions in GLP-1 receptor and metabolic pathways, but genetics alone do not predict exact medication response. Combined with biomarker assessment and provider evaluation, genetic insights can support more informed personalization discussions.

Understanding Semaglutide for Weight Loss: Benefits, Risks, and More

Semaglutide is a GLP-1 receptor agonist showing significant weight loss results in clinical trials, with average reductions of 10-22% depending on dose and population. Individual response varies based on metabolic biomarkers, genetic predispositions, and lifestyle factors. Understanding these var...